Genscript Biotech (GNNSF) Stock Forecast & Price Target

Compare

18 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GNNSF Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Genscript

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GNNSF Stock 12 Month Forecast

Average Price Target

$2.98

▲(40.57% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Genscript Biotech in the last 3 months. The average price target is $2.98 with a high forecast of $3.37 and a low forecast of $2.77. The average price target represents a 40.57% change from the last price of $2.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.36827331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.76941205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,1.939097946923077,2.058195893846154,2.177293840769231,2.2963917876923077,2.4154897346153845,2.5345876815384614,2.6536856284615387,2.7727835753846155,2.8918815223076924,3.0109794692307696,3.1300774161538465,3.2491753630769233,{"y":3.36827331,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,1.9092307692307693,1.9984615384615385,2.0876923076923077,2.176923076923077,2.266153846153846,2.355384615384615,2.4446153846153846,2.533846153846154,2.623076923076923,2.712307692307692,2.8015384615384615,2.890769230769231,{"y":2.98,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,1.8930316961538463,1.9660633923076924,2.0390950884615386,2.1121267846153846,2.185158480769231,2.258190176923077,2.331221873076923,2.4042535692307694,2.477285265384616,2.5503169615384618,2.6233486576923077,2.696380353846154,{"y":2.76941205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.08,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.37

Average Price Target$2.98

Lowest Price Target$2.77

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

$3.16→$3.37

Buy

58.88%

Upside

Reiterated

11/21/25

Guotai Haitong Sticks to Its Buy Rating for Genscript Biotech (GNNSF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.75→$2.77

Buy

30.63%

Upside

Reiterated

11/14/25

Huatai Securities Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

$2.81

Buy

32.75%

Upside

Reiterated

10/16/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

$3.16

Buy

49.24%

Upside

Reiterated

08/24/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

$2.96

Buy

39.42%

Upside

Reiterated

08/22/25

Yang Huang

J.P. Morgan

$2.06→$3.08

Buy

45.48%

Upside

Reiterated

08/21/25

J.P. Morgan Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.75

Buy

29.91%

Upside

Reiterated

08/19/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

08/18/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

$3.34

Buy

57.61%

Upside

Reiterated

08/18/25

Unknown Analyst

CICC

Not Ranked

CICC

$2.76

Buy

30.33%

Upside

Reiterated

08/18/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

07/23/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.52

Buy

18.75%

Upside

Reiterated

03/15/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

$2.39→$2.81

Buy

32.75%

Upside

Reiterated

03/14/25

We lift our PT for GenScript and maintain our OW rating on the company due to three things: 1) GenScript's leading-edge technology platform and industry position in protein and the gene synthesis area with limited qualified competitors; 2) recovery order trend in the CRO and CDMO segments with eased geopolitical overhangs, and 3) outperforming enzyme business thanks to growing wallet share from key account clients as well as accelerated ex-China market expansion.

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

03/13/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

$2.7

Buy

27.30%

Upside

Reiterated

03/13/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

$3.16→$3.37

Buy

58.88%

Upside

Reiterated

11/21/25

Guotai Haitong Sticks to Its Buy Rating for Genscript Biotech (GNNSF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.75→$2.77

Buy

30.63%

Upside

Reiterated

11/14/25

Huatai Securities Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

$2.81

Buy

32.75%

Upside

Reiterated

10/16/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

$3.16

Buy

49.24%

Upside

Reiterated

08/24/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

$2.96

Buy

39.42%

Upside

Reiterated

08/22/25

Yang Huang

J.P. Morgan

$2.06→$3.08

Buy

45.48%

Upside

Reiterated

08/21/25

J.P. Morgan Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.75

Buy

29.91%

Upside

Reiterated

08/19/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

08/18/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

$3.34

Buy

57.61%

Upside

Reiterated

08/18/25

Unknown Analyst

CICC

Not Ranked

CICC

$2.76

Buy

30.33%

Upside

Reiterated

08/18/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

07/23/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

$2.52

Buy

18.75%

Upside

Reiterated

03/15/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

$2.39→$2.81

Buy

32.75%

Upside

Reiterated

03/14/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$3.69

Buy

74.28%

Upside

Reiterated

03/13/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

$2.7

Buy

27.30%

Upside

Reiterated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genscript Biotech

1 Month

xxx

Success Rate

1/2 ratings generated profit

Average Return

-12.05%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -12.05% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+3.45%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +3.45% per trade.

1 Year

Yang HuangJ.P. Morgan

Success Rate

0/2 ratings generated profit

Average Return

-9.30%

reiterated a buy rating 4 months ago

Copying Yang Huang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.30% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

+14.65%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +14.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GNNSF Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GNNSF has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. GNNSF average Analyst price target in the past 3 months is 2.98.

Each month's total comprises the sum of three months' worth of ratings.

GNNSF Financial Forecast

GNNSF Earnings Forecast

Next quarter’s earnings estimate for GNNSF is -$0.01 with a range of -$0.01 to -$0.01. The previous quarter’s EPS was -$0.02. GNNSF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.

GNNSF Sales Forecast

Next quarter’s sales forecast for GNNSF is $441.15M with a range of $441.15M to $441.15M. The previous quarter’s sales results were $519.52M. GNNSF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GNNSF has Performed in-line its overall industry.

GNNSF Stock Forecast FAQ

What is GNNSF’s average 12-month price target, according to analysts?

Based on analyst ratings, Genscript Biotech’s 12-month average price target is 2.98.

What is GNNSF’s upside potential, based on the analysts’ average price target?

Genscript Biotech has 40.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GNNSF a Buy, Sell or Hold?

Genscript Biotech has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Genscript Biotech’s price target?

The average price target for Genscript Biotech is 2.98. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.37 ,the lowest forecast is $2.77. The average price target represents 40.57% Increase from the current price of $2.12.

What do analysts say about Genscript Biotech?

Genscript Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of GNNSF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Genscript Biotech (GNNSF) Stock Forecast & Price Target

GNNSF Analyst Ratings

GNNSF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genscript Biotech

GNNSF Analyst Recommendation Trends

GNNSF Financial Forecast

GNNSF Earnings Forecast

GNNSF Sales Forecast

GNNSF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts